ISL1 Promotes Enzalutamide Resistance in Castration-resistant Prostate Cancer (CRPC) Through Epithelial to Mesenchymal Transition (EMT)

Overview

Journal Sci Rep

Specialty Science

Date 2021 Nov 10

PMID 34753990

Citations 5

Authors

Jae Duck Choi

Tae Jin Kim

Byong Chang Jeong

Hwang Gyun Jeon

Seong Soo Jeon

Min Yong Kang

Seon Yong Yeom

Seong Il Seo

Affiliations

Soon will be listed here.

Abstract

Abnormal expression of insulin gene enhancer-binding protein 1 (ISL1) has been demonstrated to be closely associated with cancer development and progression in several cancers. However, little is known about ISL1 expression in metastatic castration-resistant prostate cancer (CRPC). ISL1 has also been recognized as a positive modulator of epithelial-mesenchymal transition (EMT). In this study, we focused on ISL1 which showed maximum upregulation at the mRNA level in the enzalutamide-resistant cell line. Accordingly, we found that ISL1 was overexpressed in enzalutamide-resistant C4-2B cells and its expression was significantly related to EMT. Our findings reveal the important role of ISL1 in androgen receptor (AR)-dependent prostate cancer cell growth; ISL1 knockdown reduced the AR activity and cell growth. ISL1 knockdown using small-interfering RNA inhibited AR, PSA, and EMT-related protein expression in C4-2B ENZR cells. In addition, knock-down ISL1 reduced the levels of AKT and p65 phosphorylation in C4-2B ENZR cells and these suggest that knock-down ISL1 suppresses EMT in part by targeting the AKT/NF-κB pathway. Further, ISL1 downregulation could effectively inhibit tumor growth in a human CRPC xenograft model. Together, the present study shows that downregulation of ISL1 expression is necessary for overcoming enzalutamide resistance and improving the survival of CRPC patients.

Citing Articles

Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance.

Jian J, Wang X, Zhang J, Zhou C, Hou X, Huang Y Front Endocrinol (Lausanne). 2024; 15:1360430.

PMID: 38887275 PMC: 11180744. DOI: 10.3389/fendo.2024.1360430.

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.

Ashrafizadeh M, Zhang W, Tian Y, Sethi G, Zhang X, Qiu A Cancer Metastasis Rev. 2024; 43(1):229-260.

PMID: 38374496 DOI: 10.1007/s10555-024-10168-9.

Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer.

Jindal R, Nanda A, Pillai M, Ware K, Singh D, Sehgal M Comput Struct Biotechnol J. 2023; 21:1498-1509.

PMID: 36851919 PMC: 9957767. DOI: 10.1016/j.csbj.2023.01.031.

Identification of Diagnostic Markers in Infantile Hemangiomas.

Huang S, Chen R, Gao S, Shi Y, Xiao Q, Zhou Q J Oncol. 2022; 2022:9395876.

PMID: 36504560 PMC: 9731762. DOI: 10.1155/2022/9395876.

Tumor cell-derived exosomal lncRNA LOC441178 inhibits the tumorigenesis of esophageal carcinoma through suppressing macrophage M2 polarization.

Chen J, Chen Z, Hu W, Cai D Eur J Histochem. 2022; 66(4).

PMID: 36250676 PMC: 9627538. DOI: 10.4081/ejh.2022.3510.

References

Graham T, Zhau H, Odero-Marah V, Osunkoya A, Kimbro K, Tighiouart M . Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008; 68(7):2479-88. DOI: 10.1158/0008-5472.CAN-07-2559. View

Yilmaz M, Christofori G . EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28(1-2):15-33. DOI: 10.1007/s10555-008-9169-0. View

Lyttle B, Li J, Krishnamurthy M, Fellows F, Wheeler M, Goodyer C . Transcription factor expression in the developing human fetal endocrine pancreas. Diabetologia. 2008; 51(7):1169-80. DOI: 10.1007/s00125-008-1006-z. View

Jarvinen P, Laiho M . LIM-domain proteins in transforming growth factor β-induced epithelial-to-mesenchymal transition and myofibroblast differentiation. Cell Signal. 2011; 24(4):819-25. DOI: 10.1016/j.cellsig.2011.12.004. View

Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S, Sternberg C . Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2015; 9:3325-39. PMC: 4492664. DOI: 10.2147/DDDT.S69433. View

Li Y, Chan S, Brand L, Hwang T, Silverstein K, Dehm S . Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2012; 73(2):483-9. PMC: 3549016. DOI: 10.1158/0008-5472.CAN-12-3630. View

Liu C, Lou W, Zhu Y, Yang J, Nadiminty N, Gaikwad N . Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res. 2015; 75(7):1413-22. PMC: 4383695. DOI: 10.1158/0008-5472.CAN-14-3080. View

Chaffer C, Marjanovic N, Lee T, Bell G, Kleer C, Reinhardt F . Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013; 154(1):61-74. PMC: 4015106. DOI: 10.1016/j.cell.2013.06.005. View

Bronnum H, Andersen D, Schneider M, Nossent A, Nielsen S, Sheikh S . Islet-1 is a dual regulator of fibrogenic epithelial-to-mesenchymal transition in epicardial mesothelial cells. Exp Cell Res. 2012; 319(4):424-35. DOI: 10.1016/j.yexcr.2012.12.019. View

10.

Cai C, Liang X, Shi Y, Chu P, Pfaff S, Chen J . Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev Cell. 2003; 5(6):877-89. PMC: 5578462. DOI: 10.1016/s1534-5807(03)00363-0. View

11.

Zhang Z, Cheng L, Li J, Farah E, Atallah N, Pascuzzi P . Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. Cancer Res. 2018; 78(12):3147-3162. PMC: 6004251. DOI: 10.1158/0008-5472.CAN-17-3006. View

12.

Ware K, Somarelli J, Schaeffer D, Li J, Zhang T, Park S . Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. Oncotarget. 2016; 7(31):50507-50521. PMC: 5226599. DOI: 10.18632/oncotarget.10476. View

13.

Shi Q, Wang W, Jia Z, Chen P, Ma K, Zhou C . ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth. Oncotarget. 2016; 7(24):36489-36500. PMC: 5095015. DOI: 10.18632/oncotarget.9269. View

14.

Ferraldeschi R, Welti J, Luo J, Attard G, de Bono J . Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 2014; 34(14):1745-57. PMC: 4333106. DOI: 10.1038/onc.2014.115. View

15.

Shibue T, Weinberg R . EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017; 14(10):611-629. PMC: 5720366. DOI: 10.1038/nrclinonc.2017.44. View

16.

Li L, Sun F, Chen X, Zhang M . ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis. Onco Targets Ther. 2018; 11:781-789. PMC: 5818873. DOI: 10.2147/OTT.S144241. View

17.

Penning T . Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). J Steroid Biochem Mol Biol. 2015; 153:105-13. PMC: 4568163. DOI: 10.1016/j.jsbmb.2015.05.010. View

18.

Lee S, Lou W, Nadiminty N, Lin X, Gao A . Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate. 2005; 64(2):160-7. DOI: 10.1002/pros.20218. View

19.

Pfaff S, Mendelsohn M, Stewart C, Edlund T, Jessell T . Requirement for LIM homeobox gene Isl1 in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation. Cell. 1996; 84(2):309-20. DOI: 10.1016/s0092-8674(00)80985-x. View

20.

Wadosky K, Koochekpour S . Androgen receptor splice variants and prostate cancer: From bench to bedside. Oncotarget. 2017; 8(11):18550-18576. PMC: 5392349. DOI: 10.18632/oncotarget.14537. View